Yes - this mgmt team is much more professional than many small biotechs.
They manage well and communicate well.
Interesting to see the number of trials they want to start before end of the year. If all of them really start, we will see secondary offering in Q1-2017 - not a bad thing to use money from new investors at market price as long as the price is right.
Without any conclusion of trials and new secondary - I expect opportunity to buy this share at 11-12 range
News 
Market Data 
Discover 
